Evidence map›Paper›PMID 42519161›Full record

ArticlePhysics and imaging in radiation oncology2026

Systematic gravity-induced posterior tumour drift in free-breathing lung stereotactic ablative radiotherapy.

Lars Merring-Mikkelsen, Hella M B Sand, Mads H Brincker

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lars Merring-MikkelsenDepartment of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark.
Hella M B SandDepartment of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark.
Mads H BrinckerDepartment of Medical Physics, Oncology, Aalborg University Hospital, Aalborg, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Intra-fractional respiratory tumour motion is a known challenge in lung stereotactic ablative radiotherapy (SABR), as it can compromise target dose coverage. Gravity-induced tumour baseline drift during free-breathing carries the same risk but remains uncharacterised. This study aimed to quantify posterior tumour drift in peripheral lung SABR, investigate predictive factors, and evaluate tumour dose coverage. Materials and methods: In total, 97 patients (102 tumours) treated with 67.5 Gy in 3 fractions were analysed. Pre- and post-treatment cone beam computed tomography (CBCT) imaging quantified intra-fractional shifts at the first and second fraction. Temporal linear regression determined patient-specific drift rates. Correlations between drift rates and patient and tumour parameters were assessed. Plans were recalculated for worst-case drifts exceeding the 4 mm posterior planning target volume (PTV) margin. Results: Systematic posterior drift was observed, with mean vertical shifts of -1.45 mm at the first fraction and - 1.24 mm at the second fraction (both Conclusions: Gravity-induced posterior drift represents a systematic, clinically significant phenomenon in free-breathing lung SABR. In 15.7% of patients, drifts exceeded planning margins, with potentially severe target underdosage. Routine post-treatment CBCT verification is recommended to identify at-risk patients, enabling intervention at subsequent fractions to ensure treatment accuracy.

Indexed as

Cone beam computed tomographyFree-breathing radiotherapyGravity-induced motionIntra-fractional tumour driftLung cancerStereotactic ablative radiotherapy

Identifiers

PMID42519161
PMCPMC13382430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.